Journal Article Describes HemogloBind™ To Reduce Analytical Interferences from Hemolysis

MONMOUTH JUNCTION, N.J. - May 25, 2022 - PRLog -- Biotech Support Group reports on a research publication describing the simplicity and efficiency of their hemoglobin depletion products for cytokine/chemokine immunoassay measurements. The citation is:

Phillippi, Danielle T., et al. "Inhaled diesel exhaust particles result in microbiome-related systemic inflammation and altered cardiovascular disease biomarkers in C57Bl/6 male mice (https://particleandfibretoxicology.biomedcentral.com/articles/10.1186/s12989-022-00452-3)." Particle and fibre toxicology 19.1 (2022): 1-29.

The gut microbiota plays a vital role in host homeostasis and is associated with inflammation and cardiovascular disease (CVD) risk. Exposure to particulate matter (PM) is a known mediator of inflammation and CVD. However, the role of inhaled traffic-generated PM on the gut microbiome and its corresponding systemic effects are not well-characterized. Thus, the study investigated exposure to inhaled diesel exhaust particles (DEP) on mice. To help determine systemic inflammation, plasma concentrations of G-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-9, IL-12(p20) IL-13, IL-15, LIF, LIX, MCP-1, M-CSF, MIG, MIP-2, RANTES, and TNF-α were measured using a Mouse Cytokine/Chemokine Magnetic Bead Panel following HemogloBind treatment; the article stating "HemogloBind was added to plasma samples (1:1 ratio), vortexed for 30 s, inverted for 10 min, and centrifuged for 2 min at 9000 RPMs." Key findings were that inhaled DEP exposure alters small intestinal microbial profiles to which play a role in systemic inflammation and early CVD biomarkers.

"The large amount of hemolysis in mice plasma samples presents a special challenge for quantitative analysis. This article is one more example of how HemogloBind™ can reduce interference from hemoglobin, without compromising the recovery and measurement of very low concentration analytes like cytokines." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™ (http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin...)

Click here for more information on all of our Hemoglobin Removal products (https://www.biotechsupportgroup.com/Articles.asp?ID=452)

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:

Matthew Kuruc
732-274-2866
mkuruc@biotechsupportgroup.com (mailto:sales@biotechsupportgroup.com)